GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phio Pharmaceuticals Corp (FRA:44R3) » Definitions » Cyclically Adjusted Price-to-FCF

Phio Pharmaceuticals (FRA:44R3) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Phio Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted Price-to-FCF for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Phio Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Phio Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Phio Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

Phio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Phio Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Phio Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Phio Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Phio Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phio Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Phio Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.



Phio Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Phio Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Phio Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.802/131.7762*131.7762
=-0.802

Current CPI (Mar. 2024) = 131.7762.

Phio Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -7,425.000 100.560 -9,729.944
201409 -6,227.273 100.428 -8,171.108
201412 -4,043.750 99.070 -5,378.738
201503 -5,542.424 99.621 -7,331.374
201506 -1,632.000 100.684 -2,135.980
201509 -1,749.000 100.392 -2,295.778
201512 -1,469.000 99.792 -1,939.819
201603 -2,627.000 100.470 -3,445.553
201606 -1,655.000 101.688 -2,144.692
201609 -1,428.000 101.861 -1,847.384
201612 -650.500 101.863 -841.529
201703 -873.000 102.862 -1,118.396
201706 -742.667 103.349 -946.944
201709 -464.000 104.136 -587.159
201712 -465.000 104.011 -589.129
201803 -386.750 105.290 -484.041
201806 -265.333 106.317 -328.872
201809 -245.714 106.507 -304.011
201812 -52.931 105.998 -65.804
201903 -62.129 107.251 -76.336
201906 -46.595 108.070 -56.816
201909 -49.026 108.329 -59.637
201912 -48.638 108.420 -59.116
202003 -13.365 108.902 -16.172
202006 -4.357 108.767 -5.279
202009 -3.485 109.815 -4.182
202012 -4.457 109.897 -5.344
202103 -3.088 111.754 -3.641
202106 -2.406 114.631 -2.766
202109 -2.183 115.734 -2.486
202112 -1.935 117.630 -2.168
202203 -2.871 121.301 -3.119
202206 -2.027 125.017 -2.137
202209 -3.133 125.227 -3.297
202212 -2.238 125.222 -2.355
202303 -2.215 127.348 -2.292
202306 -1.480 128.729 -1.515
202309 -1.114 129.860 -1.130
202312 -0.942 129.419 -0.959
202403 -0.802 131.776 -0.802

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Phio Pharmaceuticals  (FRA:44R3) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Phio Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Phio Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Phio Pharmaceuticals (FRA:44R3) Business Description

Traded in Other Exchanges
Address
257 Simarano Drive, Suite 101, Marlborough, MA, USA, 01752
Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immuno-oncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The company's pipeline products include PH-762, PH-804, PH-790, and others.

Phio Pharmaceuticals (FRA:44R3) Headlines

No Headlines